Mice and rats are the most important models for HBC, and has enabled scientists to understand the fundamental events that cause breast cancer initiation, development and progression (28). In addition, mouse models offer a number of opportunities for studying breast cancer treatment and prevention (29).

Inbred mice were first used as a unique model for studying susceptibility to specific cancer types, including breast cancer, in 1920 (30). The use of inbred strains demonstrated that certain hormonal, environmental and genetic factors, including mouse mammary tumor virus (MMTV), have important roles in determining the susceptibility to breast cancer (30). Inbred mice have a carbon-copy genetic background, so they are expected to generate analogous responses to similar treatments and exposures (31). Gathering data from standardized collections around the world allows cancer researchers to investigate virtually any phenotype of interest, and utilize the depth and breadth of knowledge on that model system.

In 1980, GEMMs were developed through the removal of specific tumor suppressor genes or the overexpression of specific oncogenes, in a germline-specific manner (32). These models have been used to assess signal transduction pathways, pathobiology and gene expression signatures. They have also been used to evaluate the efficacy of chemoprevention strategies (33). Using GEMMs, researchers have the ability to examine the effect of single or multiple genes on the evolution of tumors in the breast. GEMMs have conditional alleles that induce the mutations necessary for specific cancer types (34). In a number of cases, GEMMs more faithfully, compared with other animal models, represent the full biochemical, proteomic, genetic, phenotypic and histological characteristic features of specific human tumors (35). In 2007, a novel approach using the avian leucosis virus receptor A as a transgene targeted to the mammary gland was published (36). These models are advantageous as they mimic the condition of initiated cells within a field of normal cells. Furthermore, if a means to modify the vector to infect particular subpopulations is developed, the phenotypes arising from certain cell subtypes can be traced more accurately (36).

Several rodent studies have demonstrated that exposure to cancer-causing agents, including radiation or chemicals produces specific tumors, have effects of these agents resulting in uncontrolled cell growth due to mutations and alterations (37,38). These models recapitulate the multi-stage and time-dependent development of tumor pathogenesis in the reaction to tumor-promoting agents and etiologically relevant environmental carcinogens (39). Researchers generated these models in outbred rodent breeds of various genetic backgrounds, and reported a high frequency of organ-specific cancer types with highly reproducible phenotypes. Furthermore, these models have histopathological, biochemical and molecular features that resemble the developmental consequences of specific human tumors, which make them clinically and biologically important (39,40).

As with traditional xenograft models developed in syngeneic hosts and GEMMs, carcinogen-induced tumor models allow the assessment and modulation of the function of humoral and cellular immune components in tumor immune surveillance and evasion mechanisms. The participating role of chronic and acute inflammatory processes in cancer development and progress is clearly represented in this model (41,42). The carcinogen-induced tumor model is particularly relevant given the epidemiological and experimental association between human tumor development and chronic inflammation (43). In addition, these models have been used in chemoprevention studies to assess the therapeutic effects on tumor development and growth (29,44). A number of experimental agents were determined to be useful in the management or prevention of certain human tumors in their analogous organ-specific, carcinogen-induced cancer models (45–48).

The molecular, phenotypic and histological similarities, the general predilection for metastasis, and the utility in inflammatory and immune response studies make these models beneficial translational biology systems for drug discovery and early non-clinical drug development stages.

Currently, mice are used in xenograft experiments, in particular severe combined immunodeficiency mice and nude mice. These two strains naturally induce single gene mutations that compromise the immune system. HBC cell lines are relatively easily transplanted into these animal models. For invasive breast cancer, the reported success is 7–20% (49). This range depends on a number of factors, including the implantation site, strain, hormonal supplementation and the age of the mice. However, pre-invasive breast cancer samples, including DCIS, were reported to be more successful in developing xenografts (50,51).

The rat is considered to be the first domesticated laboratory mammal used as a model for HBC research, used as early as 1912. Rats are easier to use in research than mice, as they are larger in size (52,53). A number of comparative studies have illustrated the histological similarities between HBC and rat mammary tumors (50,51). The incidence of breast cancer in rat models is either spontaneous, or generated by the transgenesis of activated oncogenes or the induction of mutations in tumor suppressor genes (54). Chemical carcinogens have been used to induce breast cancer in the rat mammary gland for >50 years, most commonly N-nitroso-N-methylurea or 7,12-dimethylbenz(a)anthracene (55–57). These chemically-induced tumor models have been frequently utilized in the investigation of hormone-dependent breast tumors, and the role of pregnancy in preventing breast tumors (58–60). It was identified that chemically-induced tumors in rats are hormone-dependent adenocarcinomas, in contrast to the majority of mammary tumors that arise in GEMMs (51).

Although rodents are the most frequently used animal models in cancer research, there are a number of limitations to their role. Firstly, there are significant differences between the biology of rodents and their tumors, and that of humans and their tumors. There are immanent differences in the developmental programs of rodents and humans. Size is a notable difference, which affects the number, differentiation and maturation of transformed cells (61). In addition, observable tumors in mice require rapid growth progression relatively, as the lifespan of rodents is relatively short compared with that of humans. Mice can develop severe malignant lesions with multiple genetic alterations within 6–18 months (61). Furthermore, rodent cells are much easier, compared with human cells, to transform with chemical carcinogens or oncogene transfection in vitro, possibly due to their relatively poor control of genetic stability, less effective DNA repair, or altered regulation of gene expression (62).

Another notable difference is in the tumor pathology and biology observed between rodents and humans. Fewer genetic changes are required for rodent cell transformation in vitro, and potentially also in vivo (37). For example, ~50% of HBCs are hormone-dependent at diagnosis, whereas the majority of mouse tumors are hormone-independent, with notably low ER and progesterone receptor (PR) levels (61).

Although rodents are intrinsically more susceptible than humans to carcinogenesis, in wild-type rodents, sporadic cancers are relatively rare (1). In the past, mouse breeds prone to mammary tumors were produced by vertical transmission through milk or Bittner factor, which was later demonstrated to be due to MMTV (63,64). By contrast, viruses are not convincingly involved in HBC oncogenesis, except as probable cofactors (64). Furthermore, rodent cells are easily immortalized (65,66). Primary human cells and mouse cells also exhibit considerable differences in telomerase regulation and telomere dynamics. Telomeres are considerably longer in laboratory mice (40–60 kb) compared with that of humans (10 kb), and telomerase is highly expressed in the tissues of adult mice (67). Cancer cells in humans avoid replicative senescence by maintaining telomeres through telomerase reactivation and other mechanisms, which may not be analogous to tumor development in mice (67).

Although the morphological patterns of lesions in humans and rodents initially appear to be similar, the detailed features of the majority of mouse tumors are not similar to HBCs, and cannot be classified as the same pathological grades and types (68,69). Another major difference is that small animals, including rats and mice, consume higher oxygen levels on a per-cell basis, compared with large animals (70). This results in distinct cellular microenvironments, particularly in comparatively hypoxic and avascular tumors, in which hypoxia-induced genes may influence differentiation and growth to an extent that may be unrepresentative of these processes in human tumor development (71).

Despite the usefulness of GEMMs in breast cancer research, it is difficult to regulate the extent of GEMM gene expression due to multiple copies of one gene, which may be inserted into the genome (72). Another limitation of these models is that the removal of tumor suppressor genes, if not initially intended to the mammary gland, may have lethal effects on the neonate or fetus (29). GEMMs also exhibit fundamental differences at the organism and cell levels. GEMMs usually reproduce highly specific tumor formations, follow all lesion progression aspects and primarily their design depends on the awareness of tumor genetics of human (62,72). During the use of transgenic mice, the type and degree of genetic abnormalities, which create disease, must be determined in association with those that create the disease in humans, in order to evaluate if they disagree and therefore meaning that they are unsatisfactory models (62). Asynchronous tumor development in the transgenic host is considered a major disadvantage of GEMMs (73). These models are frequently characterized by low penetrance, miscellaneous tumor frequency, and latent growth properties and tumor development (69,71). Another challenging problem in establishing GEMMs of certain cancer types is the scarcity of tissue-specific promoters, which manage transgene expression in the adult cells of the targeted tissue (74). Furthermore, GEMMs incur significant cost, time and effort for the development and maintenance required to produce analytically meaningful data (32). In addition, as in the majority of rodents, the metastatic patterns vary from human cases (32). In humans, breast cancer usually spreads via the lymphatic system, beginning in local lymph nodes, and spreading to the bone, liver, brain and the lung (75). Whilst in rodents, mammary tumors metastasize particularly to the lung via the blood (76).

In spite of the important role of carcinogen-induced models, they still have basic restraints for regular usage in the early stages of drug discovery (77). Even though these models require minimal initial cost for implementation, they require significant time and high cost for maintenance (77).

While the rat model serves an important role in breast cancer research, there are a number of disadvantages to its use. One limitation is that rat mammary tumors rarely metastasize (51). Compared with mice, the limited availability of rat genetic engineering strategies-specifically nuclear transfer for gene knockouts-has reduced the extensive use of rats as genetic models for the disease (78). A mutagenesis strategy for effectively generating breast cancer-associated (BRCA) 1 and BRCA2 gene mutants was developed (79); however, this method still requires more efficient technologies for the complete gene knockouts used in breast cancer investigation.

A previous study focused on feline mammary tumors to identify the similarities between feline and human disease (80). Studies examining the similarities between human premalignant lesions and feline mammary intraepithelial lesions (IELs) observed that the latter are characterized by a spontaneous onset and high prevalence, similar to humans, as well as all the morphological features of human pre-invasive breast tumors (81). These lesions were also distinguished by the loss of PR and ER expression, promoting the cat as a model for pre-invasive ER- and PR-negative breast tumors (82). Weijer et al (83) reported that, as in humans, feline tumor lesion size, method of growth and histological grade are associated with disease prognosis. Additionally, it was indicated that feline mammary carcinomas are able to provide a suitable model for comparative studies to examine therapeutic interventions, and serve as an intermediate model for the study of mammary tumor histogenesis and etiology (83–86).

Despite the similarities determined between human and feline disease that make the cat as a good model for HBC studies, there is significant time used to gather the minimum number of cats required for a single study within a limited time period (80). Another factor that may prevent the results of a study from being homogeneous, is that the study is reliant on pet owners when applying postoperative treatment in cases that are not in hospitals and following up the study (81). Additionally, the high cost required for studies on cats is considered a large disadvantage (85).

In recent decades, clinical and molecular similarities have been identified between HBC and canine mammary tumors (CMT) (87). The clinical similarities include the spontaneous tumor incidence, onset age, hormonal etiology and the identical course of the disease. Furthermore, the factors that affect the clinical outcome, including the tumor size, clinical stage and lymph node invasion, are identical (88). Fig. 1 depicts the histopathological similarities of mammary intraepithelial lesions between canine mammary tumor and human breast cancer. The molecular characteristics, including steroid receptor, epidermal growth factor (EGF), proliferation markers, metalloproteinase and cyclooxygenase overexpression, and p53 mutation, also mimic HBC (88). Table I demonstrated the similarities between canine mammary tumor and human breast cancer.

The reported incidence of HBC and CMT has increased recently (89–91), due to the frequent widespread usage of mammography screening, and the increased awareness of dog owners (88). The higher incidence of CMT provides an increased sample size for clinical trials in comparative medicine.

As in human females, the most common spontaneous malignancy in female dogs is mammary neoplasia (92), and premalignant lesions are prevalent in canine mammary glands (93). In females, breast cancer development is affected by estrogen; similarly, non-spayed female dogs <2 years old have a 4-fold higher risk of tumor occurrence compared with spayed dogs of the same age (94–96).

During puberty, steroid hormones are essential for mammogenesis (97); during pregnancy, the complete development of lobules and alveoli is induced by the stimulation of progesterone and estrogen (97). In CMT and HBC, ER expression is associated with the pathological features of the disease and the degree of tumor differentiation (98).

In CMT, it was identified that larger tumors with skin ulcerations and reduced prognosis exhibit a reduced level of ERα expression (99). In humans, ERβ has a greater associated with benign tumors, and its higher expression in a tumor of a lower malignancy grade is an indicator of a relatively good prognosis (99). The expression of ERβ in HBC has been associated with an extended survival time in patients with ERα-negative tumors treated with tamoxifen (100). Divergences in ER expression have a significant effect on endocrine therapy; therefore, selective ER modulators that act as full agonists for ERβ and antagonists for ERα may be effective in CMT treatment, particularly as a chemoprevention strategy (101).

PR expression has been demonstrated as an important indicator of breast cancer recurrence in humans (102). A negative PR status is associated with a reduced prognosis (101,103). A combination of PR and ER expression status has also been associated with overall survival. ER⁻/PR⁻ cases are associated with the worst survival rates, followed by ER⁻/PR⁺, ER⁺/PR⁻ and ER⁺/PR⁺ (42).

In CMT, ER and PR expression are common in normal and benign tissues. It was observed that ERα⁺/PR⁺ was the most common status of benign tumors, whereas an ERα⁻/PR⁺ status was twice as common as ERα⁺/PR⁺ in malignant cancer (77). Malignant tumors tend to lose hormonal dependency as the disease progresses towards metastasis, therefore these tumors and their metastases have a tendency to be ER⁻/PR⁻ (95). In HBC, the ER⁻/PR⁻ status is associated with a poorer prognosis (104).

Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) have been investigated in human breast carcinogenesis (45,105). Previously, it was identified that the inhibition of GH/IGF-1 may prevent pre-neoplastic breast disease and cancer (46). In dogs, progestin stimulates the mammary gland tissue to locally produce GHs (48). It was assumed that the epithelial hyperplasia that was observed following the administration of progestin and the subsequent biosynthesis by the mammary gland was mediated by autocrine GHs (47,105). The full-length canine GH receptor (GHR) sequence in CMT has expanded homology with the GHR sequence of humans and various other species (106). This evidence may support the utility of GH in comparative pathology. According to novel data, an association between GH and progesterone levels in CMT homogenates has been identified, indicating that the progesterone/GH axis has an evident role in CMT (107). The GH/IGF-1 axis is also significant in CMT prognosis (108). Pre-surgical serum concentrations of the IGF-1 content of the malignant lesions and tissue GH levels are associated with a reduction in the post-surgical survival rate (109). Another study demonstrated that the concentrations of serum IGF-1 in female dogs with malignant tumors were higher compared with in healthy controls (110). The predictive value of IGF-1 and GH in mammary tumors was established for the first time in veterinary and human medicine (111). This evidence has facilitated novel therapeutic approaches, including the use of pegvisomant as a GH-competitive antagonist (108,111).

Prolactin is characterized by its lactogenic activity, as well as functioning as a growth factor in breast tumors (112). It has been observed in breast cancer that prolactin supplementation promotes the survival of mammary tissue, and that the clinical condition of patients may improve following hypophysectomy, indicating a hormonal dependency on prolactin (112). HBC cells and tumors co-express sex steroid hormone and prolactin receptors, which are cross-regulated (113). This may clarify the collaboration between sex steroid hormones and prolactin during neoplastic growth and mammary development, in particular between prolactin and progesterone (113). It is proposed that prolactin and steroid hormones act as local growth factors, stimulating malignant tumor proliferation (109). In addition, it was determined that clinical tumor features were associated with prolactin levels in tissue homogenates, demonstrating an association with steroid hormone levels (114). Further studies are required to understand the effect of prolactin on prognosis in veterinary medicine.

In recent decades, a number of molecular markers associated with tumor development have been identified. Of the number of genes identified to be responsible for breast cancer occurrence and development in humans, a number were also demonstrated to serve an essential role in the carcinogenesis of mammary tumors in dogs (115). These markers include BRCA gene mutations, EGF receptor (EGFR), Ki-67, human epidermal growth factor receptor (HER2)/neu, p53, p63, matrix metalloproteinases, phosphatase and tensin homolog, heat-shock proteins, mucins, maspin, Sialyl Lewis X antigen and cyclooxygenase-2 (88). Uva et al (116) examined the oncogene expression common between human and canine breast cancer, and reported significant similarities in the signaling networks that regulate mammary cancer biology. Germline mutations in BRCA genes have been associated with a relatively high risk (4-fold) of mammary tumor development in certain breeds of dogs (117,118). An association between the expression of mutated BRCA1 or BRCA2, and RAD51 recombinase (RAD51), a DNA-repairing protein that is, when upregulated, associated with the development of mammary tumors, was also reported in dogs (119). Nieto et al (120) revealed that the expression of BRCA1 was reduced in malignant CMT lesions. Reverse transcription-quantitative polymerase chain reaction on laser-microdissected tissue samples of normal mammary gland epithelia, simple canine adenomas and adenocarcinomas free from non-neoplastic epithelial and stromal cells were used to study the differential mRNA expression of RAD51, BRCA1 and BRCA2 (121). In that study, the expression of BRCA1 was not clearly associated with the histological criteria of malignancy, in contrast to human tumors; however, BRCA2 and BRCA1 were overexpressed in 50% of lymph node metastases, whereas RAD51 was overexpressed in 50% of primary tumors and 80% of lymph node metastases. According to these conflicting results, a reduction in expression in more malignant cells may be expected. The conclusion was that this overexpression was induced by the inhibition of proliferation due to a negative regulatory loop in which BRCA2 was produced by cellular proliferation (122).

EGFR, also known as HER1, is considered a molecular marker in triple-negative breast cancer, including ER⁻, PR⁻ and HER2/neu⁻ (123). In CMT, cases with positive EGFR expression are associated with reduced disease-free and overall survival rates. Additionally, it was reported that benign and hyperplastic lesions consistently express EGFR in the myoepithelial cells of humans and dogs (124). It has been indicated that in tissues with high concentrations of progesterone and EGF, a mechanism involving the angiogenic effects of EGF and the induction of proliferation by progesterone may exist in CMT (125).

HER2/neu is another important prognostic factor (126). HER2/neu⁺ tumor-specific therapy has yielded promising treatment results (126). In the study by Rungsipipat et al (127), out of 79 CMT cases, HER2/neu was expressed in a ~19% adenocarcinomas and ~50% benign tumors, including simple and complex adenomas. In a study of malignant CMT and HBC, the rate of HER2/neu expression was similar (20 and 30%) (128). Kerns et al (128) detected the co-expression of HER2/neu and p53 mutation, which induced malignant cell behavior. Similar to humans, four phenotypic subtypes have been identified in malignant CMT, according to the immunohistochemical expression of HER2 and ER: HER2 overexpressing (ER⁻/HER2⁺, 8.3%); basal-like (ER⁻/HER2⁻, 29.2%); luminal A (ER⁺/HER2⁻, 44.8%); and luminal B (ER⁺/HER2⁺, 13.5%) (129,130). Individuals diagnosed with the basal-like subtype have reduced survival rates (131). This indicates the molecular heterogeneity of HBC and CMT, providing further evidence that CMT is a potential model for the study of HBC.

The Ki-67 antigen is a nuclear protein highly expressed in proliferating cells prior to mitosis (132). Ki-67 labeling has been identified in different types of human and canine tumors (133). For humans, immunohistochemical determination of Ki-67 expression in mammary carcinomas has been indicated as a prognostic marker for relapse-free survival time (134). Proliferating cell nuclear antigen (PCNA) and other proliferation markers have been studied in combination with Ki-67 (135). The reliable prognostic value of PCNA in other types of malignancy has been described by several studies (135); however, it was determined to be a poor prognostic indicator for human mammary carcinoma (135). The immunohistochemical expression of Ki-67 and PCNA has also been studied in CMT; the expression of Ki-67 has been associated with a poor prognosis (133). PCNA was observed to be more frequently expressed in malignant CMT than in normal mammary glands, hyperplasia and benign tumors (136). Similar to HBC, the expression of Ki-67 in benign and malignant tumors was reported to be considerably associated with the presence of remote metastases, as well as associated with the histological criteria of malignancy and the PCNA index (137).

Following DNA damage, the p53 tumor suppressor gene has an important role in regulating cell growth. Deregulated cell proliferation occurs following mutations of this gene, which causes tumor formation and progression (138). In HBC, p53 gene mutation leads to the accumulated nuclear expression of the p53 protein. This event has prognostic value, and is usually indicative of a relatively poor survival time (139). In CMT, the expression of mutant p53 has also been identified as a valuable prognostic marker (140). The frequency of p53 mutation in CMT is ~20%, which is analogous to that detected in HBC (141). In humans and dogs, mutations in the conserved domains of p53 appear to have an essential role in the carcinogenesis of mammary glands (142). It was identified that p53 mutations in CMT occur within the second, fourth and fifth exons, and Ala125Val point mutations are common between human and canine p53 genes (143). A study of aggressive CMT carcinomas indicated an association between p53 mutations and the aggressive type (143), which has also been concluded in HBC studies (143). Additionally, as the arrangement of p53 gene products and coding exons are similar in both species, there may be a shared therapeutic target (141).

The p63 gene is from the p53 gene family. p63 is involved in the regeneration of epithelial stem cells and is not considered a tumor suppressor gene (144). It was demonstrated to be overexpressed in the basal epithelial cells of various human cancer types (144). The p63 gene may act as a tumor promoter in specific pathological conditions (145). In humans, p63 is overexpressed in the breast carcinoma basal phenotype, in which it regulates the growth and differentiation of stratified epithelia (146). In humans, p63 is a specific and sensitive indicator for myoepithelial cells (147). Strongly positive p63 staining indicates myoepithelial differentiation in papillary carcinomas (147). p63 has been determined to be a strong myoepithelial cell indicator in dogs, and is important for the differentiation of myoepithelial or basal cells from stromal myofibroblasts (148). Furthermore it was determined that the overexpression of p63 was associated with stem and myoepithelial cells, which may explain the histogenesis of CMT (149).

In order to confirm that the dog is a model that represents HBC in every aspect, x-ray mammography has been used to define the similarities between human and dog specimens. X-ray mammography is currently used to detect human DCIS by identifying the presence of microcalcifications (150). Such microcalcifications are identified in 42–72% of DCIS cases (150,151). The existence of microcalcifications alone is used to diagnose ~90% of nonpalpable DCIS (152). Mammogram data are classified by a Breast Imaging Reporting and Data System (153) (BI-RADS), according to the morphology and distribution of calcifications, into three types: Typical benign, intermediate concern, and higher expectation of malignancy (153). The detection of DCIS has improved due to mammography use; however, whether the detection of DCIS by mammography leads to a decrease in the breast cancer mortality rate has yet to be fully investigated (154). Thus, they assessed the dog as a model for studying pre-invasive and invasive breast tumors. The study identified mammographic abnormalities in canine mammary pre-invasive lesions, benign tumors and malignant tumors that were similar to the abnormalities associated with HBC. These abnormalities include the pattern, presence and distribution of microcalcifications and macrocalcifications (154). BI-RADS categorization was thus considered a precise method for the detection of mammary malignant lesions in canines, with high specificity and sensitivity (155).

In a study of 88 mammary glands excised from 40 female dogs of different breeds, mammographic features, including microcalcifications, macrocalcifications, mass margin and shape, and their association with the histological diagnosis, were identified in 78/88 mammary glands (155). The remaining 10 mammary glands exhibited a normal mammographic appearance (155). Calcification was identified in 42/78 glands (54%), of which 19 glands (24%) had macrocalcifications and 23 glands (29%) contained microcalcifications. Lesions with microcalcifications (29%) were amorphous/indistinct (5/23, 22%), linear branching (4/23, 17%) or pleomorphic regional and diffuse (14/23, 61%), and the majority were associated with atypical IELs and malignant tumors. On the other hand, 11/19 lesions with macrocalcifications (57%) were ‘popcorn-like’, with regional distribution in four glands (24%) and diffuse distribution in seven glands (36%). The other 8/19 (42%) were round, with regional localization. Lesions with macrocalcifications were diagnosed as malignant and benign tumors, primarily of the complex type or IELs without atypia. In addition, mass margins and shape were evaluated by mammography in 54/78 (69%) glands. Of the benign lesions, 21/26 (81%) were oval or round masses and 12/26 (46%) had circumscribed margins. Of the malignant lesions, 12/25 (48%) were irregular in shape, and 22/25 (88%) exhibited indistinct margins. The ultrasound abnormalities of 46/78 mammary lesions corresponded with histological data. Using ultrasound, calcifications were identified in 41% of the lesions and 53% were associated with malignant tumors. An oval shape was observed in 25/40 (62.5%) benign or malignant tumors. Of the benign lesions, 78% featured a well-circumscribed margin, whereas 80% of malignant lesions featured irregular margins (155).

The study indicated that dog and human mammary neoplasms form similar microcalcifications and macrocalcifications. It also indicated a similar process of cancer pathogenesis between humans and dogs. Furthermore, it was determined that the sonographic and mammographic features of benign and malignant canine mammary IELs were associated with the histopathological data. The BI-RADS categorization was concluded to be an excellent predictor of malignant canine mammary lesions. In addition, the study indicated that dogs are suitable models for HBC (155).

Using pets as a model for studying has the same limitations as in case of cats, including high cost and time consumption, and reliance on the owner of the pet post-treatment (156). These are considered significant limitations for using dogs as a model for HBC.